Parity and risk of developing breast cancer according to tumor subtype: A systematic review and meta-analysis

Li, Chenyang; Fan, Zeyu; Lin, Xiao; Cao, Mingli; Song, Fang; Song, Fengju

doi:10.1016/j.canep.2021.102050

Cited by 29 publications

(15 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In contrast, physical exercise (metabolic equivalents to 3-5 h moderate pace walking per week) has been demonstrated to be efficient in reducing breast cancer risk (LoE2a/B/ AGO++). Pregnancy related factors (number of full-term pregnancies (LoE2b/B), first delivery before the age of 30 years (LoE2b/B), duration of breast feeding (LoE3a/B) may be preventive for breast cancer, whereas PCO syndrome (LoE3b/C), assisted reproduction (LoE2b/B), and abortion (LoE2b/B) do not influence the risk for EBC [6].…”

Section: Options For Primary Prevention and Lifestyle Factorsmentioning

confidence: 99%

AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2022

et al. 2022

View full text Add to dashboard Cite

Introduction: The AGO (Arbeitsgemeinschaft Gynäkologische Onkologie, German Gynecological Oncology Group) Task Force on Diagnosis and Treatment of Breast Cancer as an interdisciplinary team consists of specialists from gynecological oncology, pathology, diagnostic radiology, medical oncology, and radiation oncology with a special focus on breast cancer. Methods: The updated evidence-based treatment recommendation 2022 for early breast cancer (EBC) and metastatic breast cancer (MBC) of the AGO Task Force have been released. Results and Conclusion: This paper captures the update of EBC.

show abstract

Section: Options For Primary Prevention and Lifestyle Factorsmentioning

confidence: 99%

AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2022

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Parity, particularly if first birth occurs at an early age, is protective against estrogen receptor (ER)-positive BC, the numerically predominate subtype after menopause. In contrast, a recent meta-analysis found that parity was unrelated to risk of human epidermal growth factor receptor-2 (HER-2) over-expressing BC or triple negative BC (BC that does not express ER, progesterone receptor [PR], or HER-2) [ 1 ]. A 2010 pooled analysis of 15 studies found that nulliparity was substantially less frequent among triple-negative BCs as compared with ER-positive luminal BCs [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

Reproductive risk factors associated with breast cancer in young women by molecular subtype

Ruddy¹,

Vierkant²,

Jahan³

et al. 2022

The Breast

View full text Add to dashboard Cite

“…The analysis of female BC patients' distribution according to favorable (≥ 5) and unfavorable (< 5) hormone receptor expression values among 113 BC patients demonstrates that the number of ER with values ≥ 5 is by 5.65 times greater than that of ER with values < 5, the number of PR with values ≥ 5 is by 1.63 times only greater than that of PR with values < 5, while the number of the HER2 with favorable values of 2 and 3 is almost equal to that of the HER2 with unfavorable values of 0 and 1 [8]. The results from a systematic review and meta-analysis of 16 case-control and four cohort studies retrieved from eight mainstream databases up to January 12, 2021, show that among 1135131 participants, there are 7795 luminal A, 3576 luminal B, 1794 overexpressing HER2-negative, and 5192 TNBC cases [10]. The combined odds ratios for ever parity versus nulliparity indicate a reduction by 34% of the luminal A subtype risk and a by 29% of the luminal B subtype risk.…”

Section: Discussionmentioning

confidence: 99%

Immunohistochemical Marker Patterns in Female Breast Cancer

Yaneva

Dimitrova

Ivanov

et al. 2022

Open Access Maced J Med Sci

View full text Add to dashboard Cite

BACKGROUND: Breast cancer (BC) represents the most common cancer in women worldwide and in Bulgaria. Its great medico-social importance determines the intensive complex research devoted to BC prevention, early diagnosis and management. AIM: The objective of the present investigation is to reveal some essential peculiarities of four main immunohistochemical markers used in the diagnosis of molecular subtypes of female BC. MATERIALS AND METHODS: During the period between December 1, 2017 and November 30, 2020, we examined a total of 128 randomly selected female BC patients operated on in Marko Markov Specialized Hospital for Active Treatment of Oncological Diseases of Varna, Bulgaria. We analyze BC molecular types and four immunohistochemical markers in BC patients. The expression of estrogen (ER) and progesterone (PR) receptors is assessed in mammary gland biopsies and surgical specimens by using the indirect immunoperoxidase method with EnVision™ FLEX MiniKit, that of HER2 with HercepTest™ and that of Ki-67 proliferation index with Leica Aperio Scan Scope AT2 device. The positivity and negativity of these receptors in single molecular subtypes is evaluated. RESULTS: The luminal B HER2-positive and the luminal B HER2-negative subtypes are most common - in 36.72% and 35.16% of the cases, respectively. TNBC subtype is established in 11.72%) the luminal A - in 8.59% and the non-luminal HER2-positive subtype - in 7.81% of the cases. The positive expression is statistically significantly more common in ER (t=8.972; p<0.0001) and PR (t=2.828; p<0.01), while the negative expression insignificantly prevails in HER2. CONCLUSION: Our immunohistochemical results in female BC patients prove the role of single receptor expression for the proper and timely decision making about the necessity and benefit of additional chemotherapy in selected surgically treated cases.

show abstract

Parity and risk of developing breast cancer according to tumor subtype: A systematic review and meta-analysis

Cited by 29 publications

References 31 publications

AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2022

AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2022

Reproductive risk factors associated with breast cancer in young women by molecular subtype

Immunohistochemical Marker Patterns in Female Breast Cancer

Contact Info

Product

Resources

About